NOVARTIS AG |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 105.9 USD | -0.19% |
|
+2.71% | +4.90% |
| 02:31pm | Abu Dhabi, Novartis to Collaborate on Genomics Research for Cancer Therapy | MT |
| 06:43am | Novartis, Roche's Genentech Among Companies Facing Italian Competition Watchdog Inquiry Over Eye Drug | MT |
ETFs positioned on Novartis AG
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 8.01% | 13 M€ | -.--% | ||
| 1.52% | 9 M€ | -4.31% | - |
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows:
- oncology (29.9%);
- immunology (17.2%);
- cardiovascular, renal and metabolic diseases (14.1%);
- neuroscience (8.9%).
The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products.
At the end of 2023, Novartis AG had 33 production sites worldwide.
Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).
Sector
Pharmaceuticals
Calendar
2024-06-18
- Citi European Healthcare Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
106.5
USD
Average target price
110.2
USD
Spread / Average Target
+3.47%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +45.42% | 754B | |
| +40.95% | 630B | |
| -5.69% | 352B | |
| +19.79% | 331B | |
| +9.50% | 298B | |
| +18.79% | 250B | |
| -0.78% | 216B | |
| +6.37% | 164B | |
| +0.66% | 163B |
- Stock Market
- Equities
- NOVN Stock
- NVS Stock
- Funds and ETFs Novartis AG
